Regulatory News
Wednesday, June 29, 2016
BRIEF-Cascadian Therapeutics receives Ont-380 fast track designation from FDA for treatment of advanced breast cancer
* Says company is actively recruiting patients for a
randomized, double-blind, placebo-controlled phase 2 study
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment